{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"15"}]}],"title":"Total deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}],"title":"Deaths while on treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Death within 30 days of last dose of study drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"14"}]}],"title":"Deaths during follow-up period"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"23"}],"units":"Participants"}],"description":"Deaths that occurred during the study are presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","groups":[{"description":"Cycles 1-2 (21-day cycle):\n\nDay 1: pemetrexed 500 mg/m\\^2 + cisplatin 75 mg/m\\^2\n\nDay 2: LY2603618 130 to 275 mg\n\nAfter 2 cycles, participants may have continued on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion was met.\n\nPemetrexed, cisplatin, and LY2603618 were administered IV over 10 minutes, 1 hour, and 1 hour, respectively.","id":"OG000","title":"Phase 1: Pemetrexed + Cisplatin + LY2603618"},{"description":"Cycles 1-4 (21-day cycle):\n\nBefore 25 Oct 2012:\n\nDay 1: pemetrexed 500 mg/m\\^2 + cisplatin 75 mg/m\\^2\n\nDay 2: LY2603618 dose determined from phase 1 (275 mg)\n\nAfter 25 Oct 2012:\n\nDay 1: pemetrexed 500 mg/m\\^2 + cisplatin 75 mg/m\\^2\n\nAfter 4 cycles, participants may have continued on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion was met.\n\nMaintenance therapy (every 21 days):\n\nBefore 25 Oct 2012:\n\nDay 1: pemetrexed 500 mg/m\\^2\n\nDay 2: LY2603618 dose determined from phase 1 (275 mg)\n\nAfter 25 Oct 2012:\n\nDay 1: pemetrexed 500 mg/m\\^2\n\nIf, as of 25 Oct 2012, the participant was in maintenance therapy and randomized to the experimental arm, the participant was eligible to continue with pemetrexed/LY2603618 therapy if the investigator deemed it was in the participant's best interest and the participant consented.\n\nPemetrexed, cisplatin, and LY2603618 were administered IV over 10 minutes, 1 hour, and 1 hour, respectively.","id":"OG001","title":"Phase 2: Pemetrexed + Cisplatin + LY2603618"},{"description":"Cycles 1-4 (21-day cycle):\n\nDay 1: pemetrexed 500 mg/m\\^2 + cisplatin 75 mg/m\\^2\n\nAfter 4 cycles, participants may have continued on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion was met.\n\nMaintenance therapy (every 21 days):\n\nDay 1: pemetrexed 500 mg/m\\^2\n\nPemetrexed was administered IV over 10 minutes, and cisplatin was administered IV over 1 hour.","id":"OG002","title":"Phase 2: Pemetrexed + Cisplatin"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All enrolled participants.","reportingStatus":"POSTED","timeFrame":"Randomization through 12 months after the last participant was randomized","title":"Deaths","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}